Sinopharm Hyundai (600420.SH): Calcium gluconate injection passed generic drug consistency evaluation

Zhitongcaijing · 11/26 08:49

Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. (Sinopharm Rongsheng for short), a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” for calcium gluconate injections approved and issued by the State Drug Administration to approve the consistent evaluation of the quality and efficacy of generic drugs.

Calcium gluconate injections are suitable for treating hand and foot cramps caused by calcium deficiency, acute hypokalemia, alkali poisoning, and hypoparathyroid function; allergic diseases; relief of magnesium poisoning; relief of fluorosis; cardiac resuscitation (such as relief of hyperkalemia or hypokalemia, or abnormal cardiac function caused by calcium channel blockage).